Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 82

Results For "US"

7514 News Found

Developing entrepreneurship in Ayush Sector is a priority area: Ayush Minister
Policy | December 02, 2023

Developing entrepreneurship in Ayush Sector is a priority area: Ayush Minister

Global Ayurveda Festival organising in Thiruvananthapuram from 1st to 5th December


USFDA inspection at Alkem Laboratories API manufacturing facility located at Mandva
News | December 02, 2023

USFDA inspection at Alkem Laboratories API manufacturing facility located at Mandva

The company has received Form 483 with three observations


Biocon Biologics completes Integration of Viatris' Biosimilar business
News | December 01, 2023

Biocon Biologics completes Integration of Viatris' Biosimilar business

The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone


Eugia Pharma receives USFDA approval for Budesonide Inhalation Suspension
Drug Approval | December 01, 2023

Eugia Pharma receives USFDA approval for Budesonide Inhalation Suspension

The product is expected to be launched in FY25


Aster to separate its India and GCC businesses to unlock value
News | November 29, 2023

Aster to separate its India and GCC businesses to unlock value

Both the India and GCC entities will be operated by separate dedicated management teams


BrainSpec receives FDA clearance to begin using AI-backed solution for non-invasive brain chemistry measurement
Digitisation | November 28, 2023

BrainSpec receives FDA clearance to begin using AI-backed solution for non-invasive brain chemistry measurement

First-ever brain chemistry database will allow clinicians to quickly infer brain biomarker data to support the diagnostic process in conditions such as Alzheimer's Disease


Laurus Labs acquires 87.59% stake in Laurus Bio Private
News | November 25, 2023

Laurus Labs acquires 87.59% stake in Laurus Bio Private

Laurus Labs concluded the acquisition by securing the remaining 8,333 equity shares from the promoter group shareholders


Lupin receives tentative approval from USFDA for Canagliflozin Tablets
Drug Approval | November 24, 2023

Lupin receives tentative approval from USFDA for Canagliflozin Tablets

Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor


Lupin receives approval from USFDA for Bromfenac Ophthalmic Solution
Drug Approval | November 24, 2023

Lupin receives approval from USFDA for Bromfenac Ophthalmic Solution

Bromfenac Ophthalmic Solution, 0.07% is indicated for the treatment of postoperative inflammation and reduction of ocular pain